Citadel Advisors
MRTX

Citadel Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Citadel Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-22,300
Closed -$1.31M – 15832
2023
Q4 		$1.31M Sell
22,300
-20,500
-48% -$1.15M ﹤0.01% 6140
2023
Q3 		$1.86M Buy
42,800
+31,000
+263% +$1.11M ﹤0.01% 5342
2023
Q2 		$426K Buy
11,800
+3,500
+42% +$144K ﹤0.01% 8285
2023
Q1 		$309K Sell
8,300
-122,500
-94% -$5.51M ﹤0.01% 9325
2022
Q4 		$5.93M Buy
130,800
+52,100
+66% +$3.37M ﹤0.01% 3583
2022
Q3 		$5.5M Sell
78,700
-1,900
-2% -$141K ﹤0.01% 3715
2022
Q2 		$5.41M Buy
80,600
+49,900
+163% +$3.17M ﹤0.01% 3652
2022
Q1 		$2.52M Sell
30,700
-83,200
-73% -$8.51M ﹤0.01% 5575
2021
Q4 		$16.7M Sell
113,900
-62,000
-35% -$9.63M ﹤0.01% 2254
2021
Q3 		$31.1M Buy
175,900
+120,300
+216% +$19.4M 0.01% 1540
2021
Q2 		$8.98M Sell
55,600
-48,100
-46% -$7.72M ﹤0.01% 3252
2021
Q1 		$17.8M Buy
103,700
+2,500
+2% +$495K ﹤0.01% 2122
2020
Q4 		$22.2M Buy
101,200
+17,100
+20% +$3.7M 0.01% 1690
2020
Q3 		$14M Buy
84,100
+34,700
+70% +$4.75M ﹤0.01% 1911
2020
Q2 		$5.64M Sell
49,400
-79,300
-62% -$7.69M ﹤0.01% 2923
2020
Q1 		$9.89M Sell
128,700
-75,900
-37% -$6.81M ﹤0.01% 1865
2019
Q4 		$26.4M Sell
204,600
-374,600
-65% -$36.1M 0.01% 1243
2019
Q3 		$45.1M Buy
579,200
+251,600
+77% +$23.6M 0.02% 820
2019
Q2 		$33.7M Buy
327,600
+292,000
+820% +$22.7M 0.02% 983
2019
Q1 		$2.61M Buy
+35,600
New +$2.42M ﹤0.01% 4019
2018
Q4 		– Sell
-15,000
Closed -$707K – 9918
2018
Q3 		$707K Buy
15,000
+8,900
+146% +$495K ﹤0.01% 6146
2018
Q2 		$301K Buy
+6,100
New +$230K ﹤0.01% 7208

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Citadel Advisors's MRTX Position: Q1 2024 in Review

Citadel Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 66,611 shares — an estimated $3.91M sold.

Citadel Advisors first reported a position in MRTX in Q3 2015 and held it in 31 quarters. The position peaked at $73.9M in Q2 2021. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Citadel Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Citadel Advisors sold 66,611 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $3.91M.
  • Citadel Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2015 and held it in 31 quarters.
  • Citadel Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $73.9M in Q2 2021.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.